文献速递妇科肿瘤

帕博利珠单抗治疗经治晚期宫颈癌的疗效与安全性:II期KEYNOTE-158研究结果

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
PubMed 文献 · J Clin Oncol · 2019-04-03

KEYNOTE-158是一项II期篮式研究,评估帕博利珠单抗在经治晚期宫颈癌患者中的抗肿瘤活性与安全性。98例患者接受帕博利珠单抗200 mg每3周一次治疗,客观缓解率(ORR)为12.2%(95%CI 6.5%至20.4%),所有缓解均见于PD-L1阳性肿瘤患者,该亚组ORR为14.6%(95%CI 7.8%至24.2%)。治疗相关3至4级不良事件发生率为12.2%。基于这些结果,美国食品药品监督管理局(FDA)加速批准帕博利珠单抗用于化疗期间或之后进展的晚期PD-L1阳性宫颈癌患者。

要点

  • 经治晚期宫颈癌患者接受帕博利珠单抗单药治疗,总体ORR为12.2%(95%CI 6.5%至20.4%)。
  • 所有缓解均见于PD-L1阳性(联合阳性评分≥1)肿瘤患者,该亚组ORR为14.6%(95%CI 7.8%至24.2%)。
  • 治疗相关3至4级不良事件发生率为12.2%,安全性总体可控。

核心结论

  • 帕博利珠单抗单药在晚期宫颈癌患者中显示出持久的抗肿瘤活性和可控的安全性。
  • 基于这些结果,美国食品药品监督管理局(FDA)加速批准帕博利珠单抗用于化疗期间或之后进展的晚期PD-L1阳性宫颈癌患者。

研究设计与样本

  • KEYNOTE-158(ClinicalTrials.gov注册号NCT02628067)是一项在多种癌症类型中研究帕博利珠单抗抗肿瘤活性与安全性的II期篮式研究。
  • 本文报告的是经治晚期宫颈癌患者的中期结果,共98例患者接受治疗。
  • 患者接受帕博利珠单抗200 mg每3周一次,持续2年或直至疾病进展、不可耐受毒性或医生/患者决定。
  • 前12个月每9周进行一次肿瘤影像学检查,之后每12周一次。
  • 主要终点为客观缓解率(ORR),由独立中心放射学审查按实体瘤疗效评价标准(版本1.1)评估;安全性为次要终点。

主要发现

  • 中位年龄为46.0岁(范围24至75岁),65.3%的患者东部肿瘤协作组(ECOG)体能状态评分为1。
  • 82例(83.7%)患者为程序性死亡配体1(PD-L1)阳性肿瘤(联合阳性评分≥1),其中77例曾因复发或转移性疾病接受过一线或以上化疗。
  • 中位随访时间为10.2个月(范围0.6至22.7个月)。
  • 总体ORR为12.2%(95%CI 6.5%至20.4%),包括3例完全缓解和9例部分缓解。
  • 所有12例缓解均见于PD-L1阳性肿瘤患者,该亚组ORR为14.6%(95%CI 7.8%至24.2%);在这些患者中,曾因复发或转移性疾病接受过一线或以上化疗者的ORR为14.3%(95%CI 7.4%至24.1%)。

临床怎么用

  • 基于KEYNOTE-158结果,美国食品药品监督管理局(FDA)加速批准帕博利珠单抗用于化疗期间或之后进展的晚期PD-L1阳性宫颈癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from patients with previously treated advanced cervical cancer. PATIENTS AND METHODS: Patients received pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision. Tumor imaging was performed every 9 weeks for the first 12 months and every 12 weeks thereafter. The primary end point was objective response rate (ORR), assessed per Response Evaluation Criteria in Solid Tumors (version 1.1) by independent central radiologic review. Safety was a secondary end point. RESULTS: Ninety-eight patients were treated. Median age was 46.0 years (range, 24 to 75 years), and 65.3% of patients had Eastern Cooperative Oncology Group performance status of 1. Eighty-two patients (83.7%) had programmed death-ligand 1 (PD-L1)-positive tumors (combined positive score ≥ 1), 77 having previously received one or more lines of chemotherapy for recurrent or metastatic disease. Median follow-up was 10.2 months (range, 0.6 to 22.7 months). ORR was 12.2% (95% CI, 6.5% to 20.4%), with three complete and nine partial responses. All 12 responses were in patients with PD-L1-positive tumors, for an ORR of 14.6% (95% CI, 7.8% to 24.2%); 14.3% (95% CI, 7.4% to 24.1%) of these responses were in those who had received one or more lines of chemotherapy for recurrent or metastatic disease. Median duration of response was not reached (range, ≥ 3.7 to ≥ 18.6 months). Treatment-related adverse events occurred in 65.3% of patients, and the most common were hypothyroidism (10.2%), decreased appetite (9.2%), and fatigue (9.2%). Treatment-related grade 3 to 4 adverse events occurred in 12.2% of patients. CONCLUSION: Pembrolizumab monotherapy demonstrated durable antitumor activity and manageable safety in patients with advanced cervical cancer. On the basis of these results, the US Food and Drug Administration granted accelerated approval of pembrolizumab for patients with advanced PD-L1-positive cervical cancer who experienced progression during or after chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chung HC, Ros W, Delord JP, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019. PMID: 30943124. doi:10.1200/JCO.18.01265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。